NEW YORK, March 5, 2014 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts Review released its analysts' notes regarding Boston Scientific Corporation (NYSE: BSX), Covidien plc (NYSE: COV), St. Jude Medical Inc. (NYSE: STJ), Synageva BioPharma Corp. (NASDAQ: GEVA), and Ligand Pharmaceuticals Incorporated (NASDAQ: LGND). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

--

Boston Scientific Corporation Analyst Notes

On March 3, 2014, Boston Scientific Corporation (Boston Scientific) reported that its Board of Directors has elected Edward J. Ludwig as a Director. The Company stated that the appointment of Ludwig will fill a vacancy that will result from the Board's decision to increase the number of directors comprising the Board from eleven to twelve. According to the Company, the increase in the number of directors and Ludwig's appointment to the Board were both effective March 1, 2014. The full analyst notes on Boston Scientific Corporation are available to download free of charge at:

http://www.AnalystsReview.com/03052014/BSX/report.pdf

--

Covidien plc Analyst Notes

On March 3, 2014, Covidien plc (Covidien) announced that its Puritan Bennett(TM) 980 ventilator has received European Economic Area (EEA) CE Mark approval. The Company stated that the new acute care ventilator from Covidien, which is designed to be simple, safe and smart, helps enable patients, from neonatal to adult, to breathe more naturally through some of the most innovative breath technology available. Covidien added that this ventilator system was also approved for commercial distribution in the US, Japan and Canada and will be available for sale in those countries as well as the EEA in the coming months. The full analyst notes on Covidien plc are available to download free of charge at:

http://www.AnalystsReview.com/03052014/COV/report.pdf

--

St. Jude Medical Inc. Analyst Notes

On February 28, 2014, St. Jude Medical Inc. (St. Jude Medical) reported that the Company will present at the Barclays Global Healthcare Conference on March 12, 2014 in Miami. The Company stated that John Heinmiller, Executive Vice President of St. Jude Medical, will address the conference at 10:15 a.m. EDT. St. Jude Medical added that the presentation will be webcast live via its website. The full analyst notes on St. Jude Medical Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03052014/STJ/report.pdf

--

Synageva BioPharma Corp. Analyst Notes

On March 3, 2014, Synageva BioPharma Corp. (Synageva BioPharma) reported its financial results for Q4 2013 and full year 2013. Annual total revenue decreased 10.6% YoY to $13.4 million, while Q4 2013 total revenue was down 28.8% YoY to $3.5 million. Net loss for the quarter was $30.7 million or $1.00 per diluted share, compared to net loss of $15.2 million or $0.62 per diluted share in Q4 2012. Net loss for full year 2013 was $95.5 million or $3.40 per diluted share, versus $42.9 million or $1.90 per diluted share in full year 2012. The Company stated that it expects a net loss between $190 million and $205 million for full year 2014. The full analyst notes on Synageva BioPharma Corp. are available to download free of charge at:

http://www.AnalystsReview.com/03052014/GEVA/report.pdf

--

Ligand Pharmaceuticals Incorporated Analyst Notes

On February 28, 2014, Ligand Pharmaceuticals Incorporated (Ligand) announced the submission of a supplemental New Drug Application (sNDA) to the US Food and Drug Administration (FDA) for Promacta(R) (eltrombopag) for the treatment of cytopenias (a reduction in blood cells) in patients with severe aplastic anaemia (SAA) who have had an insufficient response to immunosuppressive therapy (IST). The Company informed that SAA is a rare disorder in which the bone marrow fails to make enough new blood cells. Ligand added that there are no approved therapies available for SAA patients unresponsive to IST. According to the Company, on February 3, 2014, GSK announced that the FDA granted Breakthrough Therapy designation for Promacta in SAA. The full analyst notes on Ligand Pharmaceuticals Incorporated are available to download free of charge at:

http://www.AnalystsReview.com/03052014/LGND/report.pdf

--

About Analysts Review We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

--

=============

EDITOR NOTES: 


        
        - This is not company news. We are an independent source and our views do
          not reflect the companies mentioned.
        - Information in this release is fact checked and produced on a best efforts
          basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human
          and are prone to make mistakes. If you notice any errors or omissions, please notify
          us below.
        - This information is submitted as a net-positive to companies mentioned, to
          increase awareness for mentioned companies to our subscriber base and the investing
          public.
        - If you wish to have your company covered in more detail by our team, or wish
          to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
        - For any urgent concerns or inquiries, please contact us at compliance [at]
          AnalystsReview.com.
        - Are you a public company? Would you like to see similar coverage on your
          company? Send us a full investors' package to research [at] AnalystsReview.com for
          consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA(R) and Chartered Financial Analyst(R) are registered trademarks owned by CFA Institute.

SOURCE Analysts Review